Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BridgeBio Pharma, Inc. - Common Stock
(NQ:
BBIO
)
73.99
+0.57 (+0.78%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BridgeBio Pharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
BridgeBio to Participate in the J.P. Morgan Healthcare Conference
January 05, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
January 02, 2026
In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...
Via
MarketMinute
Topics
Economy
Intellectual Property
The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
January 02, 2026
As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the...
Via
PredictStreet
Topics
Economy
Intellectual Property
Stocks
Earnings Scheduled For October 29, 2025
↗
October 29, 2025
Via
Benzinga
Earnings Outlook For BridgeBio Pharma
↗
October 28, 2025
Via
Benzinga
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
January 02, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 22, 2025
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
↗
December 22, 2025
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
Via
The Motley Fool
Topics
Regulatory Compliance
How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint
↗
December 02, 2025
Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam.
Via
Investor's Business Daily
BridgeBio (BBIO) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
BridgeBio (BBIO) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
BridgeBio to Participate in December Investor Conferences
November 25, 2025
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 19, 2025
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 14, 2025
Via
Benzinga
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
November 10, 2025
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
November 08, 2025
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
November 07, 2025
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...
Via
MarketMinute
Topics
Artificial Intelligence
Intellectual Property
BridgeBio to Participate in November Investor Conferences
November 04, 2025
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
November 03, 2025
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
↗
October 30, 2025
The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.
Via
Investor's Business Daily
BridgeBio Pharma (NASDAQ:BBIO) Q3 2025 Revenue Beat Overshadowed by Widened Loss
↗
October 29, 2025
BridgeBio Pharma's Q3 2025 earnings show a major revenue beat driven by Attruby sales, but a widened quarterly loss led to a negative market reaction.
Via
Chartmill
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
October 29, 2025
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder
↗
October 29, 2025
BridgeBio's Encaleret met its Phase 3 endpoint in ADH1, with 76% achieving calcium targets, supporting plans for FDA and EMA submissions in 2026.
Via
Benzinga
BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results
↗
October 29, 2025
76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.
Via
Stocktwits
BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High
↗
October 29, 2025
A second positive "domino" fell for BridgeBio on Wednesday after the company reported promising results in a genetic disease.
Via
Investor's Business Daily
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
October 29, 2025
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
October 28, 2025
Via
Benzinga
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
October 28, 2025
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday
↗
October 27, 2025
Via
Benzinga
BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial
↗
October 27, 2025
BridgeBio now intends to file a new drug application for the therapy's approval in the first half of 2026.
Via
Stocktwits
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
October 27, 2025
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
